Life Science Investing Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
Life Science Investing VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
Life Science Investing Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
Life Science Investing Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
Life Science Investing Clene Reports Topline Results Demonstrating Survival Signal for CNM-Au8® in Healey ALS Platform Trial
Life Science Investing Clene to Report HEALEY ALS Platform Trial Topline Results on Monday, October 3
Life Science Investing Clene Nanomedicine Presents Updated Long-Term Survival Data from RESCUE-ALS Participants at 2022 AANEM Scientific Conference
Life Science Investing Clene Reports Second Quarter 2022 Financial Results and Recent Operating Highlights
Life Science Investing Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
Life Science Investing Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
Life Science Investing Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
